Drugs / DW1903-R2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05155072 | May → Sep 2020 | gastritis | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW1903-R2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05155072 ↗ |
| Route | Oral | “After Oral Administration of DW1903, DW1903-R1 and DW1903-R2” NCT05155072 ↗ |